scholarly journals The Metabolic Syndrome and Its Relationship to Hypertensive Target Organ Damage

2006 ◽  
Vol 8 (3) ◽  
pp. 195-201 ◽  
Author(s):  
Giuseppe Mulé ◽  
Giovanni Cerasola
2007 ◽  
Vol 20 (3) ◽  
pp. 296-303 ◽  
Author(s):  
C CUSPIDI ◽  
S MEANI ◽  
C VALERIO ◽  
C SALA ◽  
V FUSI ◽  
...  

2014 ◽  
Vol 11 (1) ◽  
pp. 40-44
Author(s):  
Yu V Zhernakova ◽  
G Kh Sharipova ◽  
I E Chazova

The metabolic syndrome is one of most socially significant and strategic problems of clinical medicine. It is known that metabolic syndrome promotes earlier and more expressed target organ damage in patients with arterial hypertension. However, correlation of the number of metabolic syndrome components with target organ damage, selection of metabolic syndrome components, influencing expressiveness on target organ damage, are studied insufficiently. In this study it is determined that with the elevating number of the metabolic syndrome components, the frequency and expressiveness of heart, kidney and vessel damage, accompanied by the increased risk of development of cardiovascular complications, increase in patients with the maximum number of the metabolic syndrome components. Moreover, it is revealed that the relative risk of simultaneous damage of heart, kidneys and vessels in patients with arterial hypertension and metabolic syndrome, apart from high blood pressure and abdominal obesity is associated with the increase of fasting glucose level.


2005 ◽  
Vol 12 (3) ◽  
pp. 175
Author(s):  
A. Ferrucci ◽  
S. Sciarretta ◽  
V. Venturelli ◽  
G. M. Ciavarella ◽  
P. De Paolis ◽  
...  

Hypertension ◽  
2021 ◽  
Vol 78 (Suppl_1) ◽  
Author(s):  
Olga Berillo ◽  
Kugeng Huo ◽  
Julio C Fraulob-Aquino ◽  
Chantal Richer ◽  
Na Li ◽  
...  

Background: Hypertension (HTN) is associated with subclinical target organ damage including cardiac, vascular and kidney injury. The immune system plays a role in hypertension and target organ damage. Activation of T cells has been reported among peripheral blood mononuclear cells (PBMCs) of patients with HTN. MicroRNAs (miRNAs) are crucial post-transcriptional regulators of immune cells. Whether miRNAs play a role in the activation of immune cells in hypertension complicated by target organ damage in humans remains unknown. We aimed to address this question by identifying differentially expressed (DE) miRNAs and their mRNA targets in PBMCs of patients with hypertension complicated or not with metabolic syndrome (MetS) or chronic kidney disease (CKD). Methods: Normotensive subjects and patients with hypertension (HTN) associated or not with at least 2 other features of MetS or CKD were studied (n=15-16). PBMCs were isolated from blood, RNA extracted for small and total RNA sequencing (RNA-seq) using Illumina HiSeq-2500 and data were analyzed using a systems biology approach. MiRDeep2 was used for novel miRNAs prediction, miRNA annotation and counting. TargetScan 7.07 was used to predict DE miRNA targets with weighted context score percentile >50%. DE genes miRNAs and mRNAs were identified with fold change (FC) >1.5 and P <0.005. DE miRNAs with FC>2 and mean read count number (MRCM) >500, and with predicted targets with MRCM>300 were validated by reverse transcription-quantitative PCR (RT-qPCR). Results: DE miRNAs, mRNAs and non-coding RNAs were identified in HTN (22, 19 and 0), MetS (57, 401 and 11) and CKD (6, 26 and 2) compared to NTN. TargetScan predicted that 7 miRNAs target 3 mRNAs in NTN, 57 miRNAs target 55 mRNAs in MetS and 3 miRNAs target 2 mRNAs in CKD. DE miR-409-5p (FC: 0.54±0.10 vs 1.00±0.09, P <0.05), miR-411-5p (FC: 0.40±0.06, vs 1.00±0.11, P <0.001) and the novel miR-pl-86 (FC: 1.96±0.17 vs 1.00±0.15, P <0.05) in MetS vs NTN were validated by RT-qPCR. RNA-seq data were correlated with RT-qPCR for miR-409-5p (R 2 =0.40, P <2.4E-07, n=55), miR-411-5p (R 2 =0.55, P <1.1E-10, n=55), miR-pl-86 (R 2 =0.37, P <5.5E-07, n=56). Conclusion: This study showed that DE miR-409-5p, miR-411-5p and miR-pl-86 may play a role in HTN associated with MetS.


Global Heart ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e124
Author(s):  
Sang-Hyun Kim ◽  
Hyang-Lim Lee ◽  
Yeon Lee ◽  
Young-Joon Seong ◽  
Hack-Lyoung Kim ◽  
...  

2005 ◽  
Vol 18 (5) ◽  
pp. A205-A206
Author(s):  
F VIAZZI ◽  
G LEONCINI ◽  
E RATTO ◽  
V VACCARO ◽  
V FALQUI ◽  
...  

2004 ◽  
Vol 22 (Suppl. 2) ◽  
pp. S16
Author(s):  
S. Meani ◽  
C. Cuspidi ◽  
V. Fusi ◽  
B. Severgnini ◽  
C. Valerio ◽  
...  

2016 ◽  
Vol 13 (4) ◽  
pp. 60-65
Author(s):  
N V Blinova ◽  
Yu V Zhernakova ◽  
I E Chazova ◽  
E V Oshchepkova

Aims: to study the target organ damage in patients with metabolic syndrome (MS) and arterial hypertension (AH) 1 degree. Design and methods. We included 20 healthy volunteers and 60 patients with MS, AH 1 degree and dyslipidemia. Office blood pressure, 24-hour ambulatory blood pressure monitoring, measurements of the endothelial vasoactive mediators, carotid ultrasonography and echocardiography had performed at baseline. Results. The majority of patients with MS and AH 1 degree had metabolic abnormalities; the levels of vasoactive mediators were higher in comparison with control group; 30% of patients had signs of atherosclerotic process in carotid arteries; 40% of patients had left ventricular hypertrophy. Conclusion: the results showed high prevalence of target organ damage in patients with MS and AH 1 degree.


Sign in / Sign up

Export Citation Format

Share Document